;PMID: 9190321
;source_file_853.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..29] = [t:0..29]
;1)sentence:[e:35..61] = [t:35..61]
;2)section:[e:65..84] = [t:65..84]
;3)section:[e:88..120] = [t:88..120]
;4)section:[e:124..237] = [t:124..237]
;5)sentence:[e:241..311] = [t:241..311]
;6)sentence:[e:312..380] = [t:312..380]
;7)sentence:[e:381..585] = [t:381..585]
;8)sentence:[e:586..752] = [t:586..752]
;9)sentence:[e:753..868] = [t:753..868]
;10)sentence:[e:869..1072] = [t:869..1072]
;11)sentence:[e:1073..1352] = [t:1073..1352]
;12)sentence:[e:1353..1471] = [t:1353..1471]
;13)sentence:[e:1472..1636] = [t:1472..1636]
;14)sentence:[e:1637..1765] = [t:1637..1765]
;15)sentence:[e:1766..1892] = [t:1766..1892]
;16)sentence:[e:1893..2068] = [t:1893..2068]
;17)sentence:[e:2069..2226] = [t:2069..2226]
;18)sentence:[e:2227..2445] = [t:2227..2445]
;19)sentence:[e:2446..2586] = [t:2446..2586]
;20)sentence:[e:2587..2700] = [t:2587..2700]
;21)sentence:[e:2701..2874] = [t:2701..2874]
;22)sentence:[e:2875..3069] = [t:2875..3069]
;23)sentence:[e:3070..3238] = [t:3070..3238]
;24)sentence:[e:3239..3347] = [t:3239..3347]
;25)sentence:[e:3348..3545] = [t:3348..3545]
;26)sentence:[e:3546..3810] = [t:3546..3810]
;27)section:[e:3814..3866] = [t:3814..3866]
;28)section:[e:3870..3914] = [t:3870..3914]

;section 0 Span:0..29
;Drugs. 1997;53 Suppl 2:18-24.
(SEC
  (FRAG (NNP:[0..5] Drugs) (.:[5..6] .) ('':[7..14] 1997;53)
        (NNP:[15..20] Suppl) (CD:[21..25] 2:18) (::[25..26] -) (CD:[26..28] 24)
        (.:[28..29] .)))

;sentence 1 Span:35..61
;[Pharmacology of tramadol]
;[52..60]:substance:"tramadol"
(SENT
  (FRAG (-LRB-:[35..36] -LSB-) (NN:[36..48] Pharmacology) (IN:[49..51] of)
        (NN:[52..60] tramadol) (-RRB-:[60..61] -RSB-)))

;section 2 Span:65..84
;[Article in French]
(SEC
  (FRAG (NN:[65..73] -LSB-Article) (IN:[74..76] in) (JJ:[77..83] French)
        (NNS:[83..84] -RSB-)))

;section 3 Span:88..120
;Dayer P, Desmeules J, Collart L.
(SEC
  (FRAG (NNP:[88..93] Dayer) (NNP:[94..95] P) (,:[95..96] ,)
        (NNP:[97..106] Desmeules) (NNP:[107..109] J,) (NNP:[110..117] Collart)
        (NNP:[118..120] L.)))

;section 4 Span:124..237
;Service de Pharmacologie Clinique et Consultation de la Douleur, Hopital 
;Cantonal Universitaire, Geneve, Suisse.
(SEC
  (FRAG (NNP:[124..131] Service) (IN:[132..134] de)
        (NNP:[135..148] Pharmacologie) (NNP:[149..157] Clinique)
        (NNP:[158..160] et) (NNP:[161..173] Consultation) (NNP:[174..176] de)
        (NNP:[177..179] la) (NNP:[180..187] Douleur) (,:[187..188] ,)
        (NNP:[189..196] Hopital) (NNP:[198..206] Cantonal)
        (NNP:[207..220] Universitaire) (,:[220..221] ,) (NNP:[222..228] Geneve)
        (NNP:[228..229] ,) (NNP:[230..236] Suisse) (.:[236..237] .)))

;sentence 5 Span:241..311
;(+/-)-Tramadol is a synthetic 4-phenyl-piperidine analogue of codeine.
;[241..255]:substance:"(+/-)-Tramadol"
;[271..299]:substance:"4-phenyl-piperidine analogue"
;[303..310]:substance:"codeine"
(SENT
  (S-HLN
    (NP-SBJ (NN:[241..255] -LRB-+/--RRB--Tramadol))
    (VP (VBZ:[256..258] is)
      (NP-PRD
        (NP (DT:[259..260] a) (JJ:[261..270] synthetic)
           (NN:[271..290] 4-phenyl-piperidine) (NN:[291..299] analogue))
        (PP (IN:[300..302] of)
          (NP (NN:[303..310] codeine)))))
    (.:[310..311] .)))

;sentence 6 Span:312..380
;It is a  central analgesic with a low affinity for opioid receptors.
;[329..338]:substance:"analgesic"
;[363..379]:substance:"opioid receptors"
(SENT
  (S
    (NP-SBJ (PRP:[312..314] It))
    (VP (VBZ:[315..317] is)
      (NP-PRD
        (NP (DT:[318..319] a) (JJ:[321..328] central) (NN:[329..338] analgesic))
        (PP (IN:[339..343] with)
          (NP
            (NP (DT:[344..345] a) (JJ:[346..349] low) (NN:[350..358] affinity))
            (PP (IN:[359..362] for)
              (NP (JJ:[363..369] opioid) (NNS:[370..379] receptors)))))))
    (.:[379..380] .)))

;sentence 7 Span:381..585
;Its selectivity for  mu receptors has recently been demonstrated, and the M1
;metabolite of tramadol,  produced by liver O-demethylation, shows a higher
;affinity for opioid receptors  than the parent drug.
;[402..414]:substance:"mu receptors"
;[455..468]:substance:"M1 metabolite"
;[472..480]:substance:"tramadol"
;[546..562]:substance:"opioid receptors"
;[580..584]:substance:"drug"
(SENT
  (S
    (S
      (NP-SBJ-1
        (NP (PRP$:[381..384] Its) (NN:[385..396] selectivity))
        (PP (IN:[397..400] for)
          (NP (SYM:[402..404] mu) (NNS:[405..414] receptors))))
      (VP (VBZ:[415..418] has)
        (ADVP-TMP (RB:[419..427] recently))
        (VP (VBN:[428..432] been)
          (VP (VBN:[433..445] demonstrated)
            (NP-1 (-NONE-:[445..445] *))))))
    (,:[445..446] ,) (CC:[447..450] and)
    (S
      (NP-SBJ
        (NP
          (NP (DT:[451..454] the)
             (NN:[455..457] M1) (NN:[458..468] metabolite))
          (PP (IN:[469..471] of)
            (NP (NN:[472..480] tramadol))))
        (,:[480..481] ,)
        (VP (VBN:[483..491] produced)
          (NP (-NONE-:[491..491] *))
          (PP (IN:[492..494] by)
            (NP-LGS (NN:[495..500] liver) (NN:[501..502] O) (HYPH:[502..503] -)
                    (NN:[503..516] demethylation)))))
      (,:[516..517] ,)
      (VP (VBZ:[518..523] shows)
        (NP
          (NP (DT:[524..525] a) (JJR:[526..532] higher) (NN:[533..541] affinity))
          (PP (IN:[542..545] for)
            (NP (JJ:[546..552] opioid) (NNS:[553..562] receptors)))
          (PP (IN:[564..568] than)
            (NP (DT:[569..572] the) (NN:[573..579] parent) (NN:[580..584] drug))))))
    (.:[584..585] .)))

;sentence 8 Span:586..752
;The rate of production of this M1 derivative (O-demethyl  tramadol), is
;influenced by a polymorphic isoenzyme of the debrisoquine-type,  cytochrome
;P450 2D6 (CYP2D6).
;[617..630]:substance:"M1 derivative"
;[632..652]:substance:"O-demethyl  tramadol"
;[686..695]:cyp450:"isoenzyme"
;[703..715]:substance:"debrisoquine"
;[723..742]:cyp450:"cytochrome P450 2D6"
;[744..750]:cyp450:"CYP2D6"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[586..589] The) (NN:[590..594] rate))
      (PP (IN:[595..597] of)
        (NP
          (NP (NN:[598..608] production))
          (PP (IN:[609..611] of)
            (NP
              (NP (DT:[612..616] this)
                 (NN:[617..619] M1) (NN:[620..630] derivative))
              (NP (-LRB-:[631..632] -LRB-)
                 (NN:[632..642] O-demethyl) (NN:[644..652] tramadol)
                (-RRB-:[652..653] -RRB-))))))
      (,:[653..654] ,))
    (VP (VBZ:[655..657] is)
      (VP (VBN:[658..668] influenced)
        (NP-1 (-NONE-:[668..668] *))
        (PP (IN:[669..671] by)
          (NP-LGS
            (NP
              (NP (DT:[672..673] a) (JJ:[674..685] polymorphic)
                  (NN:[686..695] isoenzyme))
              (PP (IN:[696..698] of)
                (NP (DT:[699..702] the) (NN:[703..715] debrisoquine)
                    (HYPH:[715..716] -) (NN:[716..720] type))))
            (,:[720..721] ,)
            (NP
              (NP (NN:[723..733] cytochrome) (NN:[734..738] P450)
                  (NN:[739..742] 2D6))
              (NP (-LRB-:[743..744] -LRB-) (NN:[744..750] CYP2D6)
                  (-RRB-:[750..751] -RRB-)))))))
    (.:[751..752] .)))

;sentence 9 Span:753..868
;Nevertheless, this affinity for mu receptors of  the CNS remains low, being
;6000 times lower than that of morphine.
;[785..797]:substance:"mu receptors"
;[829..839]:quantitative-value:"6000 times"
;[859..867]:substance:"morphine"
(SENT
  (S
    (ADVP (RB:[753..765] Nevertheless))
    (,:[765..766] ,)
    (NP-SBJ
      (NP (DT:[767..771] this) (NN:[772..780] affinity))
      (PP (IN:[781..784] for)
        (NP (SYM:[785..787] mu) (NNS:[788..797] receptors)))
      (PP (IN:[798..800] of)
        (NP (DT:[802..805] the) (NN:[806..809] CNS))))
    (VP (VBZ:[810..817] remains)
      (S
        (NP-SBJ (-NONE-:[817..817] *))
        (ADJP-PRD (JJ:[818..821] low)))
      (,:[821..822] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[822..822] *))
        (VP (VBG:[823..828] being)
          (ADJP-PRD
            (ADJP
              (NP-ADV (CD:[829..833] 6000) (NNS:[834..839] times))
              (JJR:[840..845] lower))
            (PP (IN:[846..850] than)
              (NP
                (NP (DT:[851..855] that))
                (PP (IN:[856..858] of)
                  (NP (NN:[859..867] morphine)))))))))
    (.:[867..868] .)))

;sentence 10 Span:869..1072
;Moreover, and  in contrast to other opioids, the analgesic action of tramadol
;is only partially  inhibited by the opioid antagonist naloxone, which
;suggests the existence of  another mechanism of action.
;[905..912]:substance:"opioids"
;[918..927]:substance:"analgesic"
;[938..946]:substance:"tramadol"
;[983..989]:substance:"opioid"
;[990..1000]:substance:"antagonist"
;[1001..1009]:substance:"naloxone"
(SENT
  (S
    (UCP
      (ADVP (RB:[869..877] Moreover))
      (,:[877..878] ,) (CC:[879..882] and)
      (PP (IN:[884..886] in)
        (NP
          (NP (NN:[887..895] contrast))
          (PP (TO:[896..898] to)
            (NP (JJ:[899..904] other) (NNS:[905..912] opioids))))))
    (,:[912..913] ,)
    (NP-SBJ-2
      (NP (DT:[914..917] the) (JJ:[918..927] analgesic) (NN:[928..934] action))
      (PP (IN:[935..937] of)
        (NP (NN:[938..946] tramadol))))
    (VP (VBZ:[947..949] is)
      (ADVP (RB:[950..954] only) (RB:[955..964] partially))
      (VP (VBN:[966..975] inhibited)
        (NP-2 (-NONE-:[975..975] *))
        (PP (IN:[976..978] by)
          (NP-LOC
            (NP (DT:[979..982] the) (JJ:[983..989] opioid)
                (NN:[990..1000] antagonist))
            (NP (NN:[1001..1009] naloxone))))
        (,:[1009..1010] ,)
        (SBAR-ADV
          (WHNP-1 (WDT:[1011..1016] which))
          (S
            (NP-SBJ-1 (-NONE-:[1016..1016] *T*))
            (VP (VBZ:[1017..1025] suggests)
              (NP
                (NP (DT:[1026..1029] the) (NN:[1030..1039] existence))
                (PP (IN:[1040..1042] of)
                  (NP
                    (NP (DT:[1044..1051] another) (NN:[1052..1061] mechanism))
                    (PP (IN:[1062..1064] of)
                      (NP (NN:[1065..1071] action)))))))))))
    (.:[1071..1072] .)))

;sentence 11 Span:1073..1352
;This was demonstrated by the discovery of a  monoaminergic activity that
;inhibits noradrenaline (norepinephrine) and  serotonin (5-hydroxytryptamine;
;5-HT) reuptake, making a significant  contribution to the analgesic action by
;blocking nociceptive impulses at the  spinal level.
;[1155..1168]:substance:"noradrenaline"
;[1170..1184]:substance:"norepinephrine"
;[1191..1200]:substance:"serotonin"
;[1202..1221]:substance:"5-hydroxytryptamine"
;[1223..1227]:substance:"5-HT"
;[1281..1290]:substance:"analgesic"
(SENT
  (S
    (NP-SBJ-3 (DT:[1073..1077] This))
    (VP (VBD:[1078..1081] was)
      (VP (VBN:[1082..1094] demonstrated)
        (NP-3 (-NONE-:[1094..1094] *))
        (PP-MNR (IN:[1095..1097] by)
          (NP
            (NP (DT:[1098..1101] the) (NN:[1102..1111] discovery))
            (PP (IN:[1112..1114] of)
              (NP
                (NP (DT:[1115..1116] a) (JJ:[1118..1131] monoaminergic)
                    (NN:[1132..1140] activity))
                (SBAR
                  (WHNP-2 (WDT:[1141..1145] that))
                  (S
                    (NP-SBJ-2 (-NONE-:[1145..1145] *T*))
                    (VP (VBZ:[1146..1154] inhibits)
                      (NP
                        (NP
                          (NML
                            (NML (NN:[1155..1168] noradrenaline))
                            (NML (-LRB-:[1169..1170] -LRB-)
                                 (NN:[1170..1184] norepinephrine)
                                 (-RRB-:[1184..1185] -RRB-)))
                          (NML-1 (-NONE-:[1185..1185] *P*)))
                        (CC:[1186..1189] and)
                        (NP (NN:[1191..1200] serotonin)
                          (PRN (-LRB-:[1201..1202] -LRB-)
                            (NP
                              (NP (NN:[1202..1221] 5-hydroxytryptamine))
                              (::[1221..1222] ;)
                              (NP (NN:[1223..1227] 5-HT)))
                            (-RRB-:[1227..1228] -RRB-))
                          (NML-1 (NN:[1229..1237] reuptake))))
                      (,:[1237..1238] ,)
                      (S-ADV
                        (NP-SBJ (-NONE-:[1238..1238] *))
                        (VP (VBG:[1239..1245] making)
                          (NP
                            (NP (DT:[1246..1247] a)
                                (JJ:[1248..1259] significant)
                                (NN:[1261..1273] contribution))
                            (PP (TO:[1274..1276] to)
                              (NP (DT:[1277..1280] the)
                                  (JJ:[1281..1290] analgesic)
                                  (NN:[1291..1297] action))))
                          (PP-MNR (IN:[1298..1300] by)
                            (S-NOM
                              (NP-SBJ (-NONE-:[1300..1300] *))
                              (VP (VBG:[1301..1309] blocking)
                                (NP (JJ:[1310..1321] nociceptive)
                                    (NNS:[1322..1330] impulses))
                                (PP-LOC (IN:[1331..1333] at)
                                  (NP (DT:[1334..1337] the)
                                      (JJ:[1339..1345] spinal)
                                      (NN:[1346..1351] level)))))))))))))))))
    (.:[1351..1352] .)))

;sentence 12 Span:1353..1471
;(+/-)-Tramadol is a racemic mixture of 2 enantiomers, each one  displaying
;differing affinities for various receptors.
;[1353..1367]:substance:"(+/-)-Tramadol"
;[1394..1405]:substance:"enantiomers"
;[1461..1470]:substance:"receptors"
(SENT
  (S
    (NP-SBJ (NN:[1353..1367] -LRB-+/--RRB--Tramadol))
    (VP (VBZ:[1368..1370] is)
      (NP-PRD
        (NP (DT:[1371..1372] a) (JJ:[1373..1380] racemic)
            (NN:[1381..1388] mixture))
        (PP (IN:[1389..1391] of)
          (NP
            (NP (CD:[1392..1393] 2) (NNS:[1394..1405] enantiomers))
            (,:[1405..1406] ,)
            (NP
              (NP (DT:[1407..1411] each) (CD:[1412..1415] one))
              (VP (VBG:[1417..1427] displaying)
                (NP
                  (NP (VBG:[1428..1437] differing) (NNS:[1438..1448] affinities))
                  (PP (IN:[1449..1452] for)
                    (NP (JJ:[1453..1460] various) (NNS:[1461..1470] receptors))))))))))
    (.:[1470..1471] .)))

;sentence 13 Span:1472..1636
;(+/-)-Tramadol is a  selective agonist of mu receptors and preferentially
;inhibits serotonin  reuptake, whereas (-)-tramadol mainly inhibits
;noradrenaline reuptake.
;[1472..1486]:substance:"(+/-)-Tramadol"
;[1503..1510]:substance:"agonist"
;[1514..1526]:substance:"mu receptors"
;[1555..1564]:substance:"serotonin"
;[1584..1596]:substance:"(-)-tramadol"
;[1613..1626]:substance:"noradrenaline"
(SENT
  (S
    (S
      (NP-SBJ (NN:[1472..1486] -LRB-+/--RRB--Tramadol))
      (VP
        (VP (VBZ:[1487..1489] is)
          (NP-PRD
            (NP (DT:[1490..1491] a) (JJ:[1493..1502] selective)
                (NN:[1503..1510] agonist))
            (PP (IN:[1511..1513] of)
              (NP (SYM:[1514..1516] mu) (NNS:[1517..1526] receptors)))))
        (CC:[1527..1530] and)
        (VP
          (ADVP (RB:[1531..1545] preferentially))
          (VBZ:[1546..1554] inhibits)
          (NP (NN:[1555..1564] serotonin) (NN:[1566..1574] reuptake))
          (,:[1574..1575] ,)
          (SBAR-ADV (IN:[1576..1583] whereas)
            (S
              (NP-SBJ (NN:[1584..1596] -LRB---RRB--tramadol))
              (ADVP (RB:[1597..1603] mainly))
              (VP (VBZ:[1604..1612] inhibits)
                (NP (NN:[1613..1626] noradrenaline) (NN:[1627..1635] reuptake))))))))
    (.:[1635..1636] .)))

;sentence 14 Span:1637..1765
;The  action of these 2 enantiomers is both complementary and synergistic and
;results  in the analgesic effect of (+/-)-tramadol.
;[1660..1671]:substance:"enantiomers"
;[1730..1739]:substance:"analgesic"
;[1750..1764]:substance:"(+/-)-tramadol"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1637..1640] The) (NN:[1642..1648] action))
      (PP (IN:[1649..1651] of)
        (NP (DT:[1652..1657] these) (CD:[1658..1659] 2)
            (NNS:[1660..1671] enantiomers))))
    (VP
      (VP (VBZ:[1672..1674] is)
        (ADJP-PRD (CC:[1675..1679] both) (JJ:[1680..1693] complementary)
                  (CC:[1694..1697] and) (JJ:[1698..1709] synergistic)))
      (CC:[1710..1713] and)
      (VP (VBZ:[1714..1721] results)
        (PP-CLR (IN:[1723..1725] in)
          (NP
            (NP (DT:[1726..1729] the) (JJ:[1730..1739] analgesic)
                (NN:[1740..1746] effect))
            (PP (IN:[1747..1749] of)
              (NP (NN:[1750..1764] -LRB-+/--RRB--tramadol)))))))
    (.:[1764..1765] .)))

;sentence 15 Span:1766..1892
;After oral administration, tramadol  demonstrates 68% bioavailability, with
;peak serum concentrations reached within  2 hours.
;[1793..1801]:substance:"tramadol"
;[1816..1819]:quantitative-value:"68%"
;[1884..1885]:quantitative-value:"2"
;[1886..1891]:quantitative-units:"hours"
(SENT
  (S
    (PP (IN:[1766..1771] After)
      (NP (JJ:[1772..1776] oral) (NN:[1777..1791] administration)))
    (,:[1791..1792] ,)
    (NP-SBJ (NN:[1793..1801] tramadol))
    (VP (VBZ:[1803..1815] demonstrates)
      (NP
        (NML (CD:[1816..1818] 68) (NN:[1818..1819] %))
        (NN:[1820..1835] bioavailability))
      (,:[1835..1836] ,)
      (PP (IN:[1837..1841] with)
        (NP
          (NP (NN:[1842..1846] peak) (NN:[1847..1852] serum)
              (NNS:[1853..1867] concentrations))
          (VP (VBN:[1868..1875] reached)
            (NP (-NONE-:[1875..1875] *))
            (PP-TMP (IN:[1876..1882] within)
              (NP (CD:[1884..1885] 2) (NNS:[1886..1891] hours)))))))
    (.:[1891..1892] .)))

;sentence 16 Span:1893..2068
;The elimination kinetics can be described as 2-compartmental, with a 
;half-life of 5.1 hours for tramadol and 9 hours for the M1 derivative after a
; single oral dose of 100mg.
;[1976..1979]:quantitative-value:"5.1"
;[1980..1985]:quantitative-units:"hours"
;[1990..1998]:substance:"tramadol"
;[2003..2004]:quantitative-value:"9"
;[2005..2010]:quantitative-units:"hours"
;[2019..2032]:substance:"M1 derivative"
;[2062..2065]:quantitative-value:"100"
;[2065..2067]:quantitative-units:"mg"
(SENT
  (S
    (NP-SBJ-1 (DT:[1893..1896] The) (NN:[1897..1908] elimination)
              (NNS:[1909..1917] kinetics))
    (VP (MD:[1918..1921] can)
      (VP (VB:[1922..1924] be)
        (VP (VBN:[1925..1934] described)
          (NP-1 (-NONE-:[1934..1934] *))
          (PP (IN:[1935..1937] as)
            (ADJP (CD:[1938..1939] 2) (HYPH:[1939..1940] -)
                  (JJ:[1940..1953] compartmental)))
          (,:[1953..1954] ,)
          (PP (IN:[1955..1959] with)
            (NP
              (NP (DT:[1960..1961] a) (NN:[1963..1972] half-life))
              (PP (IN:[1973..1975] of)
                (NP
                  (NP
                    (NP (CD:[1976..1979] 5.1) (NNS:[1980..1985] hours))
                    (PP (IN:[1986..1989] for)
                      (NP (NN:[1990..1998] tramadol))))
                  (CC:[1999..2002] and)
                  (NP
                    (NP (CD:[2003..2004] 9) (NNS:[2005..2010] hours))
                    (PP (IN:[2011..2014] for)
                      (NP (DT:[2015..2018] the)
                         (NN:[2019..2021] M1) (NN:[2022..2032] derivative))))))
              (PP-TMP (IN:[2033..2038] after)
                (NP
                  (NP (DT:[2039..2040] a) (JJ:[2042..2048] single)
                      (JJ:[2049..2053] oral) (NN:[2054..2058] dose))
                  (PP (IN:[2059..2061] of)
                    (NP (CD:[2062..2065] 100) (NN:[2065..2067] mg))))))))))
    (.:[2067..2068] .)))

;sentence 17 Span:2069..2226
;This explains the approximately 2-fold accumulation  of the parent drug and
;its M1 derivative that is observed during multiple dose  treatment with
;tramadol.
;[2087..2107]:quantitative-value:"approximately 2-fold"
;[2136..2140]:substance:"drug"
;[2149..2162]:substance:"M1 derivative"
;[2217..2225]:substance:"tramadol"
(SENT
  (S
    (NP-SBJ (DT:[2069..2073] This))
    (VP (VBZ:[2074..2082] explains)
      (NP
        (NP
          (NP (DT:[2083..2086] the)
            (ADJP
              (QP (RB:[2087..2100] approximately) (CD:[2101..2102] 2))
              (HYPH:[2102..2103] -) (JJ:[2103..2107] fold))
            (NN:[2108..2120] accumulation))
          (PP (IN:[2122..2124] of)
            (NP
              (NP (DT:[2125..2128] the) (NN:[2129..2135] parent)
                  (NN:[2136..2140] drug))
              (CC:[2141..2144] and)
              (NP (PRP$:[2145..2148] its)
                 (NN:[2149..2151] M1) (NN:[2152..2162] derivative)))))
        (SBAR
          (WHNP-1 (WDT:[2163..2167] that))
          (S
            (NP-SBJ-1 (-NONE-:[2167..2167] *T*))
            (VP (VBZ:[2168..2170] is)
              (VP (VBN:[2171..2179] observed)
                (NP-1 (-NONE-:[2179..2179] *))
                (PP-TMP (IN:[2180..2186] during)
                  (NP
                    (NP (JJ:[2187..2195] multiple) (NN:[2196..2200] dose)
                        (NN:[2202..2211] treatment))
                    (PP (IN:[2212..2216] with)
                      (NP (NN:[2217..2225] tramadol)))))))))))
    (.:[2225..2226] .)))

;sentence 18 Span:2227..2445
;The recommended daily dose of tramadol is between 50  and 100mg every 4 to 6
;hours, with a maximum dose of 400 mg/day; the duration of  the analgesic
;effect after a single oral dose of tramadol 100mg is about 6  hours.
;[2257..2265]:substance:"tramadol"
;[2269..2288]:quantitative-value:"between 50  and 100"
;[2288..2290]:quantitative-units:"mg"
;[2297..2303]:quantitative-value:"4 to 6"
;[2304..2309]:quantitative-units:"hours"
;[2334..2337]:quantitative-value:"400"
;[2338..2344]:quantitative-units:"mg/day"
;[2367..2376]:substance:"analgesic"
;[2412..2420]:substance:"tramadol"
;[2421..2424]:quantitative-value:"100"
;[2424..2426]:quantitative-units:"mg"
;[2430..2437]:quantitative-value:"about 6"
;[2439..2444]:quantitative-units:"hours"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[2227..2230] The) (JJ:[2231..2242] recommended)
            (JJ:[2243..2248] daily) (NN:[2249..2253] dose))
        (PP (IN:[2254..2256] of)
          (NP (NN:[2257..2265] tramadol))))
      (VP (VBZ:[2266..2268] is)
        (NP-PRD
          (NP
            (QP (IN:[2269..2276] between) (CD:[2277..2279] 50)
                (CC:[2281..2284] and) (CD:[2285..2288] 100))
            (NN:[2288..2290] mg))
          (NP-TMP
            (NP (DT:[2291..2296] every) (CD:[2297..2298] 4))
            (PP (TO:[2299..2301] to)
              (NP (CD:[2302..2303] 6) (NNS:[2304..2309] hours)))))
        (,:[2309..2310] ,)
        (PP (IN:[2311..2315] with)
          (NP
            (NP (DT:[2316..2317] a) (JJ:[2318..2325] maximum)
                (NN:[2326..2330] dose))
            (PP (IN:[2331..2333] of)
              (NP
                (NP (CD:[2334..2337] 400) (NN:[2338..2340] mg))
                (PP (SYM:[2340..2341] /)
                  (NP (NN:[2341..2344] day)))))))))
    (::[2344..2345] ;)
    (S
      (NP-SBJ
        (NP (DT:[2346..2349] the) (NN:[2350..2358] duration))
        (PP (IN:[2359..2361] of)
          (NP (DT:[2363..2366] the) (JJ:[2367..2376] analgesic)
              (NN:[2377..2383] effect)))
        (PP-TMP (IN:[2384..2389] after)
          (NP
            (NP (DT:[2390..2391] a) (JJ:[2392..2398] single)
                (JJ:[2399..2403] oral) (NN:[2404..2408] dose))
            (PP (IN:[2409..2411] of)
              (NP (NN:[2412..2420] tramadol) (CD:[2421..2424] 100)
                  (NN:[2424..2426] mg))))))
      (VP (VBZ:[2427..2429] is)
        (NP-PRD
          (QP (RB:[2430..2435] about) (CD:[2436..2437] 6))
          (NNS:[2439..2444] hours))))
    (.:[2444..2445] .)))

;sentence 19 Span:2446..2586
;Adverse effects, and nausea in particular, are dose-dependent and  therefore
;considerably more likely to appear if the loading dose is high.
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[2446..2453] Adverse) (NNS:[2454..2461] effects))
      (,:[2461..2462] ,) (CC:[2463..2466] and)
      (NP
        (NP (NN:[2467..2473] nausea))
        (PP (IN:[2474..2476] in)
          (NP (JJ:[2477..2487] particular)))))
    (,:[2487..2488] ,)
    (VP (VBP:[2489..2492] are)
      (ADJP-PRD
        (ADJP (NN:[2493..2497] dose) (HYPH:[2497..2498] -)
              (JJ:[2498..2507] dependent))
        (CC:[2508..2511] and)
        (ADJP
          (ADVP (RB:[2513..2522] therefore))
          (ADVP (RB:[2523..2535] considerably))
          (RBR:[2536..2540] more) (JJ:[2541..2547] likely)
          (S
            (NP-SBJ-1 (-NONE-:[2547..2547] *))
            (VP (TO:[2548..2550] to)
              (VP (VB:[2551..2557] appear)
                (SBAR (IN:[2558..2560] if)
                  (S
                    (NP-SBJ (DT:[2561..2564] the) (NN:[2565..2572] loading)
                            (NN:[2573..2577] dose))
                    (VP (VBZ:[2578..2580] is)
                      (ADJP-PRD (JJ:[2581..2585] high)))))))))))
    (.:[2585..2586] .)))

;sentence 20 Span:2587..2700
;The  reduction of this dose during the first days of treatment is an
;important factor  in improving tolerability.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[2587..2590] The) (NN:[2592..2601] reduction))
      (PP (IN:[2602..2604] of)
        (NP (DT:[2605..2609] this) (NN:[2610..2614] dose)))
      (PP-TMP (IN:[2615..2621] during)
        (NP
          (NP (DT:[2622..2625] the) (JJ:[2626..2631] first)
              (NNS:[2632..2636] days))
          (PP (IN:[2637..2639] of)
            (NP (NN:[2640..2649] treatment))))))
    (VP (VBZ:[2650..2652] is)
      (NP-PRD
        (NP (DT:[2653..2655] an) (JJ:[2656..2665] important)
            (NN:[2666..2672] factor))
        (PP (IN:[2674..2676] in)
          (S-NOM
            (NP-SBJ (-NONE-:[2676..2676] *))
            (VP (VBG:[2677..2686] improving)
              (NP (NN:[2687..2699] tolerability)))))))
    (.:[2699..2700] .)))

;sentence 21 Span:2701..2874
;Other adverse effects are generally similar to those  of opioids, although
;they are usually less severe, and can include respiratory  depression,
;dysphoria and constipation.
;[2758..2765]:substance:"opioids"
(SENT
  (S
    (S
      (NP-SBJ (JJ:[2701..2706] Other) (JJ:[2707..2714] adverse)
              (NNS:[2715..2722] effects))
      (VP (VBP:[2723..2726] are)
        (ADVP (RB:[2727..2736] generally))
        (ADJP-PRD (JJ:[2737..2744] similar)
          (PP (TO:[2745..2747] to)
            (NP
              (NP (DT:[2748..2753] those))
              (PP (IN:[2755..2757] of)
                (NP (NNS:[2758..2765] opioids))))))
        (,:[2765..2766] ,)
        (SBAR-ADV (IN:[2767..2775] although)
          (S
            (NP-SBJ (PRP:[2776..2780] they))
            (VP
              (VP (VBP:[2781..2784] are)
                (ADVP-TMP (RB:[2785..2792] usually))
                (ADJP-PRD (RBR:[2793..2797] less) (JJ:[2798..2804] severe)))
              (,:[2804..2805] ,) (CC:[2806..2809] and)
              (VP (MD:[2810..2813] can)
                (VP (VB:[2814..2821] include)
                  (NP
                    (NP (JJ:[2822..2833] respiratory)
                        (NN:[2835..2845] depression))
                    (,:[2845..2846] ,)
                    (NP (NN:[2847..2856] dysphoria))
                    (CC:[2857..2860] and)
                    (NP (NN:[2861..2873] constipation))))))))))
    (.:[2873..2874] .)))

;sentence 22 Span:2875..3069
;Tramadol can be administered  concomitantly with other analgesics,
;particularly those with peripheral action,  while drugs that depress CNS
;function may enhance the sedative effect of  tramadol.
;[2875..2883]:substance:"Tramadol"
;[2930..2940]:substance:"analgesics"
;[2992..2997]:substance:"drugs"
;[3060..3068]:substance:"tramadol"
(SENT
  (S
    (NP-SBJ-2 (NN:[2875..2883] Tramadol))
    (VP (MD:[2884..2887] can)
      (VP (VB:[2888..2890] be)
        (VP (VBN:[2891..2903] administered)
          (NP-2 (-NONE-:[2903..2903] *))
          (ADVP (RB:[2905..2918] concomitantly))
          (PP (IN:[2919..2923] with)
            (NP
              (NP (JJ:[2924..2929] other) (NNS:[2930..2940] analgesics))
              (,:[2940..2941] ,)
              (NP
                (NP
                  (ADVP (RB:[2942..2954] particularly))
                  (DT:[2955..2960] those))
                (PP (IN:[2961..2965] with)
                  (NP (JJ:[2966..2976] peripheral) (NN:[2977..2983] action))))))
          (,:[2983..2984] ,)
          (SBAR-ADV (IN:[2986..2991] while)
            (S
              (NP-SBJ
                (NP (NNS:[2992..2997] drugs))
                (SBAR
                  (WHNP-1 (WDT:[2998..3002] that))
                  (S
                    (NP-SBJ-1 (-NONE-:[3002..3002] *T*))
                    (VP (VBP:[3003..3010] depress)
                      (NP (NN:[3011..3014] CNS) (NN:[3015..3023] function))))))
              (VP (MD:[3024..3027] may)
                (VP (VB:[3028..3035] enhance)
                  (NP
                    (NP (DT:[3036..3039] the) (JJ:[3040..3048] sedative)
                        (NN:[3049..3055] effect))
                    (PP (IN:[3056..3058] of)
                      (NP (NN:[3060..3068] tramadol)))))))))))
    (.:[3068..3069] .)))

;sentence 23 Span:3070..3238
;Tramadol should not be administered to patients receiving monoamine  oxidase
;inhibitors, and administration with tricyclic antidepressant drugs  should
;also be avoided.
;[3070..3078]:substance:"Tramadol"
;[3128..3146]:substance:"monoamine  oxidase"
;[3147..3157]:substance:"inhibitors"
;[3183..3213]:substance:"tricyclic antidepressant drugs"
(SENT
  (S
    (S
      (NP-SBJ-2 (NN:[3070..3078] Tramadol))
      (VP (MD:[3079..3085] should) (RB:[3086..3089] not)
        (VP (VB:[3090..3092] be)
          (VP (VBN:[3093..3105] administered)
            (NP-2 (-NONE-:[3105..3105] *))
            (PP-CLR (TO:[3106..3108] to)
              (NP
                (NP (NNS:[3109..3117] patients))
                (VP (VBG:[3118..3127] receiving)
                  (NP
                     (NN:[3128..3137] monoamine) (NN:[3139..3146] oxidase)
                    (NNS:[3147..3157] inhibitors)))))))))
    (,:[3157..3158] ,) (CC:[3159..3162] and)
    (S
      (NP-SBJ-1
        (NP (NN:[3163..3177] administration))
        (PP (IN:[3178..3182] with)
          (NP (JJ:[3183..3192] tricyclic) (JJ:[3193..3207] antidepressant)
              (NNS:[3208..3213] drugs))))
      (VP (MD:[3215..3221] should)
        (ADVP (RB:[3222..3226] also))
        (VP (VB:[3227..3229] be)
          (VP (VBN:[3230..3237] avoided)
            (NP-1 (-NONE-:[3237..3237] *))))))
    (.:[3237..3238] .)))

;sentence 24 Span:3239..3347
;Tramadol has pharmacodynamic and pharmacokinetic  properties that are highly
;unlikely to lead to dependence.
;[3239..3247]:substance:"Tramadol"
(SENT
  (S
    (NP-SBJ (NN:[3239..3247] Tramadol))
    (VP (VBZ:[3248..3251] has)
      (NP
        (NP
          (NP (JJ:[3252..3267] pharmacodynamic)
            (NML-2 (-NONE-:[3267..3267] *P*)))
          (CC:[3268..3271] and)
          (NP (JJ:[3272..3287] pharmacokinetic)
            (NML-2 (NNS:[3289..3299] properties))))
        (SBAR
          (WHNP-1 (WDT:[3300..3304] that))
          (S
            (NP-SBJ-1 (-NONE-:[3304..3304] *T*))
            (VP (VBP:[3305..3308] are)
              (ADJP-PRD (RB:[3309..3315] highly) (JJ:[3316..3324] unlikely)
                (S
                  (NP-SBJ-1 (-NONE-:[3324..3324] *))
                  (VP (TO:[3325..3327] to)
                    (VP (VB:[3328..3332] lead)
                      (PP-CLR (TO:[3333..3335] to)
                        (NP (NN:[3336..3346] dependence))))))))))))
    (.:[3346..3347] .)))

;sentence 25 Span:3348..3545
;This was confirmed by  various controlled studies and postmarketing
;surveillance studies, which  reported an extremely small number of patients
;developing tolerance or instances  of tramadol abuse.
;[3530..3538]:substance:"tramadol"
(SENT
  (S
    (NP-SBJ-3 (DT:[3348..3352] This))
    (VP (VBD:[3353..3356] was)
      (VP (VBN:[3357..3366] confirmed)
        (NP-3 (-NONE-:[3366..3366] *))
        (PP (IN:[3367..3369] by)
          (NP-LGS
            (NP
              (NP
                (ADJP-2 (JJ:[3371..3378] various))
                (JJ:[3379..3389] controlled) (NNS:[3390..3397] studies))
              (CC:[3398..3401] and)
              (NP
                (ADJP-2 (-NONE-:[3401..3401] *P*))
                (JJ:[3402..3415] postmarketing) (NN:[3416..3428] surveillance)
                 (NNS:[3429..3436] studies)))
            (,:[3436..3437] ,)
            (SBAR
              (WHNP-1 (WDT:[3438..3443] which))
              (S
                (NP-SBJ-1 (-NONE-:[3443..3443] *T*))
                (VP (VBD:[3445..3453] reported)
                  (NP
                    (NP (DT:[3454..3456] an)
                      (ADJP (RB:[3457..3466] extremely) (JJ:[3467..3472] small))
                      (NN:[3473..3479] number))
                    (PP (IN:[3480..3482] of)
                      (NP
                        (S-NOM
                          (NP-SBJ (NNS:[3483..3491] patients))
                          (VP (VBG:[3492..3502] developing)
                            (NP (NN:[3503..3512] tolerance))))
                        (IN:[3513..3515] or)
                        (NP
                          (NP (NNS:[3516..3525] instances))
                          (PP (IN:[3527..3529] of)
                            (NP (NN:[3530..3538] tramadol)
                                (NN:[3539..3544] abuse))))))))))))))
    (.:[3544..3545] .)))

;sentence 26 Span:3546..3810
;Tramadol is a central acting analgesic which has been shown  to be effective
;and well tolerated, and likely to be of value for treating  several pain
;conditions (step II of the World Health Organization ladder) where  treatment
;with strong opioids is not required.
;[3546..3554]:substance:"Tramadol"
;[3575..3584]:substance:"analgesic"
;[3786..3793]:substance:"opioids"
(SENT
  (S
    (NP-SBJ (NN:[3546..3554] Tramadol))
    (VP (VBZ:[3555..3557] is)
      (NP-PRD
        (NP (DT:[3558..3559] a)
          (ADJP (JJ:[3560..3567] central) (VBG:[3568..3574] acting))
          (NN:[3575..3584] analgesic))
        (SBAR
          (WHNP-2 (WDT:[3585..3590] which))
          (S
            (NP-SBJ-2 (-NONE-:[3590..3590] *T*))
            (VP (VBZ:[3591..3594] has)
              (VP (VBN:[3595..3599] been)
                (VP (VBN:[3600..3605] shown)
                  (S
                    (NP-SBJ-2 (-NONE-:[3605..3605] *))
                    (VP (TO:[3607..3609] to)
                      (VP (VB:[3610..3612] be)
                        (ADJP
                          (ADJP-PRD
                            (ADJP (JJ:[3613..3622] effective))
                            (CC:[3623..3626] and)
                            (ADJP (RB:[3627..3631] well)
                                  (JJ:[3632..3641] tolerated)))
                          (,:[3641..3642] ,) (CC:[3643..3646] and)
                          (ADJP
                            (ADJP (JJ:[3647..3653] likely))
                            (S
                              (NP-SBJ (-NONE-:[3653..3653] *))
                              (VP (TO:[3654..3656] to)
                                (VP (VB:[3657..3659] be)
                                  (PP-PRD (IN:[3660..3662] of)
                                    (NP
                                      (NP (NN:[3663..3668] value))
                                      (PP (IN:[3669..3672] for)
                                        (S-NOM
                                          (NP-SBJ (-NONE-:[3672..3672] *))
                                          (VP (VBG:[3673..3681] treating)
                                            (NP
                                              (NP (JJ:[3683..3690] several)
                                                  (NN:[3691..3695] pain)
                                                  (NNS:[3696..3706] conditions)
                                                (PRN (-LRB-:[3707..3708] -LRB-)
                                                  (NP
                                                    (NP (NN:[3708..3712] step)
                                                        (CD:[3713..3715] II))
                                                    (PP (IN:[3716..3718] of)
                                                      (NP (DT:[3719..3722] the)
                                                        (NML
                                                             (NNP:[3723..3728] World)
                                                             (NNP:[3729..3735] Health)
                                                             (NNP:[3736..3748] Organization))
                                                        (NN:[3749..3755] ladder))))
                                                  (-RRB-:[3755..3756] -RRB-)))
                                              (SBAR (WRB:[3757..3762] where)
                                                (S
                                                  (NP-SBJ-1
                                                    (NP
                                                        (NN:[3764..3773] treatment))
                                                    (PP (IN:[3774..3778] with)
                                                      (NP
                                                          (JJ:[3779..3785] strong)
                                                          (NNS:[3786..3793] opioids))))
                                                  (VP (VBZ:[3794..3796] is)
                                                      (RB:[3797..3800] not)
                                                    (VP
                                                        (VBN:[3801..3809] required)
                                                      (NP-1
                                                            (-NONE-:[3809..3809] *)))))))))))))))))))))))))))
    (.:[3809..3810] .)))

;section 27 Span:3814..3866
;Publication Types:      Review      Review, Tutorial
(SEC
  (FRAG (NNP:[3814..3825] Publication) (NNP:[3826..3831] Types)
        (NNP:[3831..3832] :) (NNP:[3838..3844] Review) (NNP:[3850..3856] Review)
        (,:[3856..3857] ,) (NNP:[3858..3866] Tutorial)))

;section 28 Span:3870..3914
;PMID: 9190321 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[3870..3874] PMID) (::[3874..3875] :) (CD:[3876..3883] 9190321)
        (NN:[3884..3885] -LSB-) (NNP:[3885..3891] PubMed) (::[3892..3893] -)
        (NN:[3894..3901] indexed) (IN:[3902..3905] for)
        (NNP:[3906..3914] MEDLINE-RSB-)))
